云彩红，教授，博士导师

js3845金沙线路生物化学与生物物理学系 副主任

地址：北京市海淀区学院路38号

Tel/Fax: +86-10-82805386

E-mail: yunch@hsc.pku.edu.cn

Cai-Hong Yun, Ph.D. Professor

Department of Biochemistry & Biophysics

School of Basic Medical Sciences

Peking University Health Science Center

38 Xueyuan Road, Haidian District

Beijing 100191, China

Tel/Fax: +86-10-82805386

E-mail: yunch@hsc.pku.edu.cn

简历：

2019.04-今，js3845金沙线路生物化学与生物物理学系副主任

2013.10-2019.03，js3845金沙线路生物物理学系常务副主任

2011.10-今，js3845金沙线路教授、博士导师

2010.07-2011.10，哈佛大学医学院，研究科学家

2004.11-2010.06，哈佛大学医学院，博士后

1998.09-2004.06，中国科学院生物物理研究所，获博士学位

研究方向：

以冷冻电镜和X-射线晶体学为主要手段，从事结构生物学和结构药理学研究。研究兴趣主要集中于恶性肿瘤发病机理、耐药机理和抗肿瘤靶向药物的研发。

部分代表论文（截至2022-02）：

21) Lu Y(#), Fan Z(#), Zhu SJ(#), Huang X(#), Zhuang Z(#), Li Y, Deng Z, Gao L, Hong X, Zhang T, Li L, Sun X, Huang W, Zhang J, Liu Y, Zhang B, Jiang J, Gui F, Wang Z, Li Q, Song S, Huang X, Wu Q, Chen L, Zhou D, Zhang J, Yun CH(*), Chen L(*), Deng X(*). A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol Med. 2022 Jan 11;14(1):e14296. (IF 12.137, Q1)

20) Sun FH(#), Zhao P(#), Zhang N, Kong LL, Wong CCL, Yun CH(*). HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones. Nat Commun. 2021 Feb 15;12(1):1028. (IF 14.919, Q1)

19) Yan XE(#), Ayaz P(#), Zhu SJ(#), Zhao P(#), Liang L, Zhang CH, Wu YC, Li JL, Choi HG, Huang X, Shan Y(*), Shaw DE(*), Yun CH(*). Structural Basis of AZD9291 Selectivity for EGFR T790M. J Med Chem. 2020 Aug 13;63(15):8502-8511. (IF 7.446, Q1)

18) Yang J(#), Shibu MA(#), Kong L(#), Luo J, BadrealamKhan F, Huang Y, Tu ZC, Yun CH(*), Huang CY(*), Ding K(*), Lu X(*). Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. J Med Chem. 2020 Mar 12;63(5):2114-2130. (IF 7.446, Q1)

17) Shen J(#), Zhang T(#), Zhu SJ(#), Sun M, Tong L, Lai M, Zhang R, Xu W, Wu R, Ding J, Yun CH(*), Xie H(*), Lu X(*), Ding K(*). Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). J Med Chem. 2019 Aug 8; 62(15): 7302-7308. (IF 6.205, Q1)

16) He JB(#), Zhao P(#), Hu ZM, Liu S, Kuang Y, Zhang M, Li B, Yun CH(*), Qiao X(*), Ye M(*). Molecular Characterization and Structural Basis of a Promiscuous C-Glycosyltransferase from Trollius chinensis. Angew Chem Int Ed Engl. 2019 Aug 12;58(33):11513-11520. (IF 12.959, Q1)

15) Wang J(#), Chen J(#), Wu G(#), Zhang H(#), Chen S(#), Du X, Zhang L, Wang K, Fan J, Gao S, Wu X, Zhang S, Kuai B, Zhao P, Chi B, Wang L, Li G, Wong CCL, Zhou Y, Li J(*), Yun CH(*), Cheng H(*). NRDE2 negatively regulates exosome functions by inhibiting MTR4 recruitment and exosome interaction. Genes Dev. 2019 May 1;33(9-10):536-549. (IF 9.527, Q1)

14) Zhu SJ(#), Zhao P(#), Yang J, Ma R, Yan XE, Yang SY, Yang JW, Yun CH(*), Structural Insights into Drug Development Strategy Targeting EGFR T790M/C797S, Oncotarget, 2018 Jan 10;9(17):13652-13665.

13) Song C(#), Liang L(#), Jin Y, Li Y, Liu Y, Guo L, Wu C, Yun CH(*), and Yin Y(*), RCC2 is a novel p53 target in suppressing metastasis, Oncogene, 2018 Jan 4;37(1):8-17. (IF 6.634，Q1)

12) Yan XE(#), Zhu SJ(#), Liang L, Zhao P, Choi HG, Yun CH(*), Structural basis of mutant-selectivity and drug-resistance related to CO-1686, Oncotarget, 2017 Jun 21;8(32):53508-53517.

11) Chang Y(#), Lu X(#), Shibu MA(#), Dai YB(#), Luo J, Zhang Y, Li Y, Zhao P, Zhang Z, Xu Y, Tu ZC, Zhang Q, Yun CH(*), Huang CY(*), Ding K(*), Structure-Based Design of N-(3-((1H-pyrazolo[3, 4-b]pyridin-5-yl)ethynyl) Benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors, J Med Chem. 2017 Jul 13;60(13):5927-5932. (IF 6.253，Q1)

10) Wang A(#), Li X(#), Wu H(#), Zou F(#), Yan XE(#), Chen C, Hu C, Yu K, Wang W, Zhao P, Wu J, Qi Z, Wang W, Wang B, Wang L, Ren T, Zhang S, Yun CH(*), Liu J(*), Liu Q(*). Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. J Med Chem. 2017 Apr 13;60(7):2944-2962. (IF 6.253，Q1)

9) Chen JY(#), Liu L, Cao CL, Li MJ, Tan K, Yang X and Yun CH(*), Structure and function of human Naa60 (NatF), a Golgi-localized bi-functional acetyltransferase, Sci Rep, 2016 Aug 23;6:31425. (IF 4.259，Q1)

8) Fan F(#), He Z(#), Kong LL(#), Chen Q(#), Yuan Q(#), Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH(*), Deng X(*) and Zhou D(*), Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration, Sci Transl Med, 2016 Aug 17;8(352):352ra108. (IF 16.761，Q1)

7) Jia Y(#), Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ(*),Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors, Nature. 2016 May 25;534(7605):129-32. (IF 40.137，Q1)

6) Anastasi S(#), Zhu SJ(#), Ballarò C, Manca S, Lamberti D, Wang LJ, Alemà S, Yun CH(*), Segatto O(*). Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Cell. 2016 May 19;165(5):1031-4. (IF 30.410，Q1)

5) Liu L(#), Chen JY(#), Yang B, Wang FH, Wang YH(*), Yun CH(*), Active-State Structures of a Small Heat-Shock Protein Revealed a Molecular Switch for Chaperone Function, Structure, 2015 Nov 3;23(11):2066-75. (IF 5.237，Q1)

4) Yasuda H(#), Park E(#), Yun CH(#), Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ(*),Kobayashi SS(*), Costa DB(*),Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer, Sci Transl Med, 2013 Dec18;5(216):216ra177. (IF 14.414，Q1)

——回国——

3) Zhou W(#), Ercan D(#), Chen L(#), Yun CH(#), Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS(*), Jänne PA(*), Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 2009 Dec 24; 462(7276):1070-4. (IF 34.480，Q1)

2) Yun CH(#), Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, and Eck MJ(*), The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc Natl Acad Sci USA, 2008Feb 12; 105(6):2070-5. (IF 9.380，Q1)

1) Yun CH(#), Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, and Eck MJ(*), Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity, Cancer Cell, 2007 Mar; 11(3):217-27. (封面故事，IF 23.858，Q1)